Abstract
Ovarian carcinoma is the leading cause of gynecological cancer-related mortality. Cytoreductive surgery followed by combination chemotherapy including paclitaxel and a platinum compound usually results in complete remission in approximately 70% of patients. Despite this, the majority of patients will eventually relapse and die. There is, therefore, a crucial need to develop new therapeutic agents and better strategies to improve the outcome of these patients. Recently, tumor microenvironment has become an attractive target in gynecological malignancies. Angiogenesis is a complex and highly regulated process consisting in the development of new vessels from pre-existing ones. This process has been shown to have a main role in cancer beginning and progression. In ovarian cancer increased angiogenesis is associated with rapid recurrence and decreased survival. Moreover, targeting of vascular endothelial growth factor (VEGF) has produced promising results in early clinical trials, suggesting that angiogenesis plays a critical role in the development and maintenance of ovarian carcinomas. However, many questions remain open related to optimal dosing, sequencing of therapies, toxicities, patient selection, and response assessment. This article reviews the mechanisms of the angiogenic process and resumes the latest clinical studies of antivascular agents in ovarian carcinoma in a “from bench to bedside” approach.
Keywords: Ovary, cancer, angiogenesis, VEGF, Bevacizumab, targeted therapy
Current Cancer Therapy Reviews
Title: Targeting Angiogenesis in Ovarian Carcinoma
Volume: 5 Issue: 3
Author(s): Marta Mendiola, Jorge Barriuso and David Hardisson
Affiliation:
Keywords: Ovary, cancer, angiogenesis, VEGF, Bevacizumab, targeted therapy
Abstract: Ovarian carcinoma is the leading cause of gynecological cancer-related mortality. Cytoreductive surgery followed by combination chemotherapy including paclitaxel and a platinum compound usually results in complete remission in approximately 70% of patients. Despite this, the majority of patients will eventually relapse and die. There is, therefore, a crucial need to develop new therapeutic agents and better strategies to improve the outcome of these patients. Recently, tumor microenvironment has become an attractive target in gynecological malignancies. Angiogenesis is a complex and highly regulated process consisting in the development of new vessels from pre-existing ones. This process has been shown to have a main role in cancer beginning and progression. In ovarian cancer increased angiogenesis is associated with rapid recurrence and decreased survival. Moreover, targeting of vascular endothelial growth factor (VEGF) has produced promising results in early clinical trials, suggesting that angiogenesis plays a critical role in the development and maintenance of ovarian carcinomas. However, many questions remain open related to optimal dosing, sequencing of therapies, toxicities, patient selection, and response assessment. This article reviews the mechanisms of the angiogenic process and resumes the latest clinical studies of antivascular agents in ovarian carcinoma in a “from bench to bedside” approach.
Export Options
About this article
Cite this article as:
Mendiola Marta, Barriuso Jorge and Hardisson David, Targeting Angiogenesis in Ovarian Carcinoma, Current Cancer Therapy Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339409788982223
DOI https://dx.doi.org/10.2174/157339409788982223 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics Selectivity Filters to Edit Out Deleterious Side Effects in Kinase Inhibitors
Current Topics in Medicinal Chemistry Mesoporous Materials Used in Medicine and Environmental Applications
Current Topics in Medicinal Chemistry Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy
Current Drug Therapy Effect of Oil Extract from Microalgae (<i>Schizochytrium</i> sp.) on the Viability and Apoptosis of Human Osteosarcoma Cells
Current Pharmaceutical Biotechnology PARP Inhibitor Development for Systemic Cancer Targeting
Anti-Cancer Agents in Medicinal Chemistry Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery Nanoparticles in Combating Cancer: Opportunities and Limitations: A Brief Review
Current Medicinal Chemistry Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway
Recent Patents on Anti-Cancer Drug Discovery Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Current Medicinal Chemistry Regulatory Influence of Scaffolds on Cell Behavior: How Cells Decode Biomaterials
Current Pharmaceutical Biotechnology Assessment and Management of the Adnexal Mass in the Pediatric Population
Current Women`s Health Reviews Designing and Formulation Optimization of Hyaluronic Acid Conjugated PLGA Nanoparticles of Tamoxifen for Tumor Targeting
Pharmaceutical Nanotechnology Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Modeling and Proposed Molecular Mechanism of Hydroxyurea Through Docking and Molecular Dynamic Simulation to Curtail the Action of Ribonucleotide Reductase
Recent Patents on Anti-Cancer Drug Discovery